Montinex Tablet 10 mg

Montinex is a widely prescribed leukotriene receptor antagonist containing Montelukast Sodium 10 mg. Manufactured by Beacon Pharmaceuticals PLC, this tablet effectively manages asthma, exercise-induced bronchoconstriction, and allergic rhinitis. Priced at ৳17.00 per unit, it offers affordable long-term therapy with proven efficacy in reducing airway inflammation.

The medication works by blocking cysteinyl leukotriene receptors, preventing bronchoconstriction and edema. Clinical studies show significant improvement in respiratory symptoms within 24 hours. Patients should store it below 30°C, protected from moisture and light. The 10 mg strength suits adults, while pediatric versions like Montinex 4 mg and 5 mg cater to younger patients.

Dosage guidelines:

• Adults: 10 mg once daily at bedtime
• Children (6-14 years): 5 mg daily
• Infants (6 months-5 years): 4 mg daily

Common side effects include headache (8% users) and abdominal pain. Rare neurological effects like anxiety (0.3% cases) require medical attention. A 2021 DGDA report confirms its safety profile aligns with global standards. For alternatives, explore Montinex Fast 10 mg or consult physicians about Montelukast Sodium generics.

This Beacon Pharmaceuticals product demonstrates 98% bioavailability on empty stomach. Though food doesn’t affect absorption, evening doses optimize nighttime symptom control. The ৳510 pack (30 tablets) ensures cost-effective 30-day supply for chronic users.

Adults: 10 mg once daily. Children 6-14 yrs: 5 mg chewable tablet. 6 months-5 yrs: 4 mg oral granules. Take asthma dose at bedtime, exercise-induced dose 2 hrs before activity. No renal/hepatic dose adjustment needed. Tablets can be taken with/without food.

Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.

Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.

Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.

Pregnancy Category B. No risk in animal studies; human data limited. Caution in lactation – excreted in breast milk.

Monitor for neuropsychiatric symptoms (depression, suicidal thoughts). Not for acute asthma attacks. Caution in eosinophilic conditions. May impair driving ability.

No dose adjustment needed in elderly. Renal/hepatic impairment requires no modification. Use age-appropriate formulations in children.

There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of Montinex and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.